Details of the Drug

General Information of Drug (ID: DMFK9HG)

Drug Name

Escitalopram

Synonyms

Esertia; Escitalopram [INN]; Cipralex (TN); Escitalopram (INN); Esertia (TN); Lexapro (TN); S(+)-Citalopram; (+)-(S)-1-(3-(Dimethylamino)propyl)-1-(p-fluorophenyl)-5-phthalancarbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile; (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile; (S)-Citalopram

Indication

Disease Entry	ICD 11	Status	REF
Major depressive disorder	6A70.3	Approved	[1]

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

324.4

Topological Polar Surface Area (xlogp)

3.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption Tmax: The time to maximum plasma concentration (Tmax) is 1 h [2]
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Bioavailability: The bioavailability of drug is 1% [2]
Clearance: The oral plasma clearance of drug is 600 mL/min [4]
Elimination: After oral administration of escitalopram, approximately 8% of the total dose is eliminated in the urine as unchanged escitalopram and 10% is eliminated in the urine as S-desmethylcitalopram [5]
Half-life: The concentration or amount of drug in body reduced by one-half in 27 - 32 hours [6]
Metabolism: The drug is metabolized via the hepatic [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.88074 micromolar/kg/day [7]
Vd: The volume of distribution (Vd) of drug is 12-26 L/kg [4]

Chemical Identifiers

Formula: C20H21FN2O
IUPAC Name: (1S)-1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-3H-2-benzofuran-5-carbonitrile
Canonical SMILES: CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F
InChI: InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1
InChIKey: WSEQXVZVJXJVFP-FQEVSTJZSA-N

Cross-matching ID

PubChem CID: 146570
ChEBI ID: CHEBI:36791
CAS Number: 128196-01-0
DrugBank ID: DB01175
TTD ID: D08RBC
VARIDT ID: DR00419
INTEDE ID: DR0618
ACDINA ID: D00242

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serotonin transporter (SERT)	TT3ROYC	SC6A4_HUMAN	Inhibitor	[8]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[9]
Cytochrome P450 2D6 (CYP2D6)	DECB0K3	CP2D6_HUMAN	Substrate	[10]
Mephenytoin 4-hydroxylase (CYP2C19)_{Main DME}	DEGTFWK	CP2CJ_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Major depressive disorder

ICD Disease Classification

6A70.3

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Serotonin transporter (SERT)	DTT	SLC6A4	8.76E-01	7.18E-05	6.19E-04
Mephenytoin 4-hydroxylase (CYP2C19)	DME	CYP2C19	9.62E-01	2.57E-02	1.10E-01
Cytochrome P450 2D6 (CYP2D6)	DME	CYP2D6	8.70E-01	2.98E-02	1.22E-01
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	1.76E-01	1.26E-01	8.27E-01

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Escitalopram

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Vilazodone	DM4LECQ	Major	Additive serotonergic effects by the combination of Escitalopram and Vilazodone.	Depression [6A70-6A7Z]	[46]
Vortioxetine	DM6F1PU	Major	Additive serotonergic effects by the combination of Escitalopram and Vortioxetine.	Depression [6A70-6A7Z]	[46]
Isocarboxazid	DMAF1NB	Major	Additive serotonergic effects by the combination of Escitalopram and Isocarboxazid.	Depression [6A70-6A7Z]	[47]
Milnacipran	DMBFE74	Major	Additive serotonergic effects by the combination of Escitalopram and Milnacipran.	Depression [6A70-6A7Z]	[46]
Desvenlafaxine	DMHD4PE	Major	Additive serotonergic effects by the combination of Escitalopram and Desvenlafaxine.	Depression [6A70-6A7Z]	[46]
Clomipramine	DMINRKW	Major	Additive serotonergic effects by the combination of Escitalopram and Clomipramine.	Depression [6A70-6A7Z]	[48]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Escitalopram (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Major	Additive serotonergic effects by the combination of Escitalopram and Methylene blue.	Acquired methaemoglobinaemia [3A93]	[49]
Insulin-glulisine	DMQI0FU	Moderate	Increased risk of hypoglycemia by the combination of Escitalopram and Insulin-glulisine.	Acute diabete complication [5A2Y]	[50]
Insulin-aspart	DMX7V28	Moderate	Increased risk of hypoglycemia by the combination of Escitalopram and Insulin-aspart.	Acute diabete complication [5A2Y]	[51]
Ivosidenib	DM8S6T7	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Ivosidenib.	Acute myeloid leukaemia [2A60]	[52]
Midostaurin	DMI6E0R	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Midostaurin.	Acute myeloid leukaemia [2A60]	[53]
Idarubicin	DMM0XGL	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Idarubicin.	Acute myeloid leukaemia [2A60]	[53]
Arn-509	DMT81LZ	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Arn-509.	Acute myeloid leukaemia [2A60]	[53]
Gilteritinib	DMWQ4MZ	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Gilteritinib.	Acute myeloid leukaemia [2A60]	[53]
Oliceridine	DM6MDCF	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Oliceridine.	Acute pain [MG31]	[48]
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Escitalopram and Inotersen.	Amyloidosis [5D00]	[54]
Ivabradine	DM0L594	Major	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Ivabradine.	Angina pectoris [BA40]	[55]
Bepridil	DM0RKS4	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Bepridil.	Angina pectoris [BA40]	[53]
Dronedarone	DMA8FS5	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Dronedarone.	Angina pectoris [BA40]	[53]
Bedaquiline	DM3906J	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[53]
Posaconazole	DMUL5EW	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Posaconazole.	Aspergillosis [1F20]	[53]
Levalbuterol	DM5YBO1	Moderate	Increased risk of prolong QT interval by the combination of Escitalopram and Levalbuterol.	Asthma [CA23]	[56]
Pirbuterol	DMI5678	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Pirbuterol.	Asthma [CA23]	[57]
Lisdexamfetamine	DM6W8V5	Major	Additive serotonergic effects by the combination of Escitalopram and Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[48]
Dalfopristin	DM4LTKV	Minor	Decreased metabolism of Escitalopram caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[58]
Clarithromycin	DM4M1SG	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Clarithromycin.	Bacterial infection [1A00-1C4Z]	[53]
Sparfloxacin	DMB4HCT	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[59]
Troleandomycin	DMUZNIG	Minor	Decreased metabolism of Escitalopram caused by Troleandomycin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[58]
Retigabine	DMGNYIH	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Retigabine.	Behcet disease [4A62]	[53]
Eribulin	DM1DX4Q	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Eribulin.	Breast cancer [2C60-2C6Y]	[53]
Lapatinib	DM3BH1Y	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lapatinib.	Breast cancer [2C60-2C6Y]	[53]
Tucatinib	DMBESUA	Minor	Decreased metabolism of Escitalopram caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
Palbociclib	DMD7L94	Minor	Decreased metabolism of Escitalopram caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[58]
Bosutinib	DMTI8YE	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Bosutinib.	Breast cancer [2C60-2C6Y]	[53]
Trastuzumab Emtansine	DMU1LXS	Moderate	Increased risk of bleeding by the combination of Escitalopram and Trastuzumab Emtansine.	Breast cancer [2C60-2C6Y]	[60]
PF-04449913	DMSB068	Major	Increased risk of prolong QT interval by the combination of Escitalopram and PF-04449913.	Chronic myelomonocytic leukaemia [2A40]	[53]
Olodaterol	DM62B78	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Olodaterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Vilanterol	DMF5EK1	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Vilanterol.	Chronic obstructive pulmonary disease [CA22]	[56]
Indacaterol	DMQJHR7	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Indacaterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Arformoterol	DMYM974	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Arformoterol.	Chronic obstructive pulmonary disease [CA22]	[57]
Dihydrocodeine	DMB0FWL	Moderate	Additive serotonergic effects by the combination of Escitalopram and Dihydrocodeine.	Chronic pain [MG30]	[61]
Levetiracetam	DMTGDN8	Moderate	Antagonize the effect of Escitalopram when combined with Levetiracetam.	Chronic pain [MG30]	[62]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Escitalopram and Regorafenib.	Colorectal cancer [2B91]	[54]
Sevoflurane	DMC9O43	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Sevoflurane.	Corneal disease [9A76-9A78]	[53]
Probucol	DMVZQ2M	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Probucol.	Coronary atherosclerosis [BA80]	[53]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Escitalopram and Ardeparin.	Coronary thrombosis [BA43]	[54]
Pasireotide	DMHM7JS	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Pasireotide.	Cushing syndrome [5A70]	[53]
Osilodrostat	DMIJC9X	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Osilodrostat.	Cushing syndrome [5A70]	[53]
Lumacaftor	DMCLWDJ	Moderate	Increased metabolism of Escitalopram caused by Lumacaftor mediated induction of CYP450 enzyme.	Cystic fibrosis [CA25]	[63]
Ivacaftor	DMZC1HS	Minor	Decreased metabolism of Escitalopram caused by Ivacaftor mediated inhibition of CYP450 enzyme.	Cystic fibrosis [CA25]	[58]
MK-8228	DMOB58Q	Minor	Decreased metabolism of Escitalopram caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[58]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Escitalopram and Danaparoid.	Deep vein thrombosis [BD71]	[54]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Escitalopram and Rivaroxaban.	Deep vein thrombosis [BD71]	[54]
5-hydroxy-L-tryptophan	DMDWZGJ	Major	Additive serotonergic effects by the combination of Escitalopram and 5-hydroxy-L-tryptophan.	Discovery agent [N.A.]	[64]
Tetrabenazine	DMYWQ0O	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Tetrabenazine.	Dissociative neurological symptom disorder [6B60]	[53]
Deutetrabenazine	DMUPFLI	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Deutetrabenazine.	Dystonic disorder [8A02]	[53]
Ingrezza	DMVPLNC	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Ingrezza.	Dystonic disorder [8A02]	[53]
Methsuximide	DM6L5VO	Moderate	Antagonize the effect of Escitalopram when combined with Methsuximide.	Epilepsy/seizure [8A61-8A6Z]	[62]
Cenobamate	DMGOVHA	Moderate	Decreased metabolism of Escitalopram caused by Cenobamate mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[53]
Stiripentol	DMMSDOY	Moderate	Decreased metabolism of Escitalopram caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[65]
Brivaracetam	DMSEPK8	Moderate	Antagonize the effect of Escitalopram when combined with Brivaracetam.	Epilepsy/seizure [8A61-8A6Z]	[62]
Lacosamide	DMVM6QR	Moderate	Antagonize the effect of Escitalopram when combined with Lacosamide.	Epilepsy/seizure [8A61-8A6Z]	[62]
Rufinamide	DMWE60C	Moderate	Antagonize the effect of Escitalopram when combined with Rufinamide.	Epilepsy/seizure [8A61-8A6Z]	[62]
Eslicarbazepine	DMZREFQ	Moderate	Increased risk of hyponatremia by the combination of Escitalopram and Eslicarbazepine.	Epilepsy/seizure [8A61-8A6Z]	[62]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Escitalopram and Tazemetostat.	Follicular lymphoma [2A80]	[54]
Solifenacin	DMG592Q	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Solifenacin.	Functional bladder disorder [GC50]	[53]
Sunitinib	DMCBJSR	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Sunitinib.	Gastrointestinal stromal tumour [2B5B]	[53]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Escitalopram and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[54]
Fosamprenavir	DM4W9B3	Minor	Decreased metabolism of Escitalopram caused by Fosamprenavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Fostemsavir	DM50ILT	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Fostemsavir.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Cobicistat	DM6L4H2	Minor	Decreased metabolism of Escitalopram caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
Saquinavir	DMG814N	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Saquinavir.	Human immunodeficiency virus disease [1C60-1C62]	[66]
Etravirine	DMGV8QU	Moderate	Decreased metabolism of Escitalopram caused by Etravirine mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[67]
Lopinavir	DMITQS0	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[68]
Rilpivirine	DMJ0QOW	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Rilpivirine.	Human immunodeficiency virus disease [1C60-1C62]	[53]
Darunavir	DMN3GCH	Minor	Decreased metabolism of Escitalopram caused by Darunavir mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[58]
BMS-201038	DMQTAGO	Minor	Decreased metabolism of Escitalopram caused by BMS-201038 mediated inhibition of CYP450 enzyme.	Hyper-lipoproteinaemia [5C80]	[58]
Polyethylene glycol	DM4I1JP	Moderate	Increased risk of lowers seizure threshold by the combination of Escitalopram and Polyethylene glycol.	Irritable bowel syndrome [DD91]	[53]
Phenolphthalein	DM5SICT	Moderate	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Phenolphthalein.	Irritable bowel syndrome [DD91]	[53]
Glycerol phenylbutyrate	DMDGRQO	Moderate	Decreased metabolism of Escitalopram caused by Glycerol phenylbutyrate mediated inhibition of CYP450 enzyme.	Liver disease [DB90-DB9Z]	[55]
Crizotinib	DM4F29C	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Crizotinib.	Lung cancer [2C25]	[53]
Ceritinib	DMB920Z	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Ceritinib.	Lung cancer [2C25]	[53]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Escitalopram caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[69]
Osimertinib	DMRJLAT	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Osimertinib.	Lung cancer [2C25]	[53]
Selpercatinib	DMZR15V	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Selpercatinib.	Lung cancer [2C25]	[53]
Lumefantrine	DM29GAD	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lumefantrine.	Malaria [1F40-1F45]	[70]
Halofantrine	DMOMK1V	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Halofantrine.	Malaria [1F40-1F45]	[71]
Inotuzumab ozogamicin	DMAC130	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Inotuzumab ozogamicin.	Malignant haematopoietic neoplasm [2B33]	[53]
Idelalisib	DM602WT	Minor	Decreased metabolism of Escitalopram caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
IPI-145	DMWA24P	Minor	Decreased metabolism of Escitalopram caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[58]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Escitalopram and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[54]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Escitalopram and Ibrutinib.	Mature B-cell lymphoma [2A85]	[54]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Escitalopram and Ponatinib.	Mature B-cell lymphoma [2A85]	[54]
LGX818	DMNQXV8	Major	Increased risk of prolong QT interval by the combination of Escitalopram and LGX818.	Melanoma [2C30]	[53]
Dabrafenib	DMX6OE3	Moderate	Increased metabolism of Escitalopram caused by Dabrafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[55]
Danazol	DML8KTN	Minor	Decreased metabolism of Escitalopram caused by Danazol mediated inhibition of CYP450 enzyme.	Menstrual cycle bleeding disorder [GA20]	[58]
Allopregnanolone	DMNLHAC	Moderate	Additive CNS depression effects by the combination of Escitalopram and Allopregnanolone.	Mental/behavioural/neurodevelopmental disorder [6E20-6E8Z]	[72]
Exjade	DMHPRWG	Moderate	Increased risk of bleeding by the combination of Escitalopram and Exjade.	Mineral absorption/transport disorder [5C64]	[54]
Siponimod	DM2R86O	Major	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Siponimod.	Multiple sclerosis [8A40]	[70]
Fingolimod	DM5JVAN	Major	Increased risk of ventricular arrhythmias by the combination of Escitalopram and Fingolimod.	Multiple sclerosis [8A40]	[53]
Ozanimod	DMT6AM2	Moderate	Additive serotonergic effects by the combination of Escitalopram and Ozanimod.	Multiple sclerosis [8A40]	[73]
Romidepsin	DMT5GNL	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Romidepsin.	Mycosis fungoides [2B01]	[53]
Fedratinib	DM4ZBK6	Moderate	Decreased metabolism of Escitalopram caused by Fedratinib mediated inhibition of CYP450 enzyme.	Myeloproliferative neoplasm [2A20]	[53]
Nilotinib	DM7HXWT	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Nilotinib.	Myeloproliferative neoplasm [2A20]	[53]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Escitalopram and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[54]
Dasatinib	DMJV2EK	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Dasatinib.	Myeloproliferative neoplasm [2A20]	[53]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Escitalopram and Prasugrel.	Myocardial infarction [BA41-BA43]	[54]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Escitalopram and Vorapaxar.	Myocardial infarction [BA41-BA43]	[54]
E-2007	DMJDYNQ	Moderate	Antagonize the effect of Escitalopram when combined with E-2007.	Neuropathy [8C0Z]	[62]
Entrectinib	DMMPTLH	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Entrectinib.	Non-small cell lung cancer [2C25]	[53]
Dexfenfluramine	DMJ7YDS	Major	Additive serotonergic effects by the combination of Escitalopram and Dexfenfluramine.	Obesity [5B80-5B81]	[46]
Polythiazide	DMCH80F	Moderate	Increased risk of hyponatremia by the combination of Escitalopram and Polythiazide.	Oedema [MG29]	[74]
Urea	DMUK75B	Moderate	Increased risk of hyponatremia by the combination of Escitalopram and Urea.	Oesophagitis [DA24]	[74]
Levomethadyl Acetate	DM06HG5	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Levomethadyl Acetate.	Opioid use disorder [6C43]	[55]
Lofexidine	DM1WXA6	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lofexidine.	Opioid use disorder [6C43]	[53]
Rucaparib	DM9PVX8	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Rucaparib.	Ovarian cancer [2C73]	[53]
Oxymorphone	DM65AGJ	Moderate	Additive CNS depression effects by the combination of Escitalopram and Oxymorphone.	Pain [MG30-MG3Z]	[61]
Dezocine	DMJDB0Y	Moderate	Additive CNS depression effects by the combination of Escitalopram and Dezocine.	Pain [MG30-MG3Z]	[61]
Triclabendazole	DMPWGBR	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Triclabendazole.	Parasitic worm infestation [1F90]	[53]
Safinamide	DM0YWJC	Moderate	Additive serotonergic effects by the combination of Escitalopram and Safinamide.	Parkinsonism [8A00]	[73]
Rasagiline	DM3WKQ4	Major	Additive serotonergic effects by the combination of Escitalopram and Rasagiline.	Parkinsonism [8A00]	[47]
Pimavanserin	DMR7IVC	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Pimavanserin.	Parkinsonism [8A00]	[53]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Escitalopram caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[75]
Macimorelin	DMQYJIR	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Macimorelin.	Pituitary gland disorder [5A60-5A61]	[76]
Lefamulin	DME6G97	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lefamulin.	Pneumonia [CA40]	[77]
Choline salicylate	DM8P137	Moderate	Increased risk of bleeding by the combination of Escitalopram and Choline salicylate.	Postoperative inflammation [1A00-CA43]	[54]
Lonafarnib	DMGM2Z6	Moderate	Decreased metabolism of Escitalopram caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[53]
Degarelix	DM3O8QY	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Degarelix.	Prostate cancer [2C82]	[53]
ABIRATERONE	DM8V75C	Major	Increased risk of prolong QT interval by the combination of Escitalopram and ABIRATERONE.	Prostate cancer [2C82]	[53]
Enzalutamide	DMGL19D	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Enzalutamide.	Prostate cancer [2C82]	[53]
Relugolix	DMK7IWL	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Relugolix.	Prostate cancer [2C82]	[53]
Levomepromazine	DMIKFEL	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Levomepromazine.	Psychotic disorder [6A20-6A25]	[53]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Escitalopram and Epoprostenol.	Pulmonary hypertension [BB01]	[54]
Quetiapine	DM1N62C	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Quetiapine.	Schizophrenia [6A20]	[53]
Aripiprazole	DM3NUMH	Moderate	Decreased metabolism of Escitalopram caused by Aripiprazole mediated inhibition of CYP450 enzyme.	Schizophrenia [6A20]	[70]
Iloperidone	DM6AUFY	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Iloperidone.	Schizophrenia [6A20]	[53]
Paliperidone	DM7NPJS	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Paliperidone.	Schizophrenia [6A20]	[53]
Amisulpride	DMSJVAM	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Amisulpride.	Schizophrenia [6A20]	[53]
Asenapine	DMSQZE2	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Asenapine.	Schizophrenia [6A20]	[53]
Voxelotor	DMCS6M5	Minor	Decreased metabolism of Escitalopram caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[58]
Larotrectinib	DM26CQR	Minor	Decreased metabolism of Escitalopram caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[58]
Armodafinil	DMGB035	Moderate	Decreased metabolism of Escitalopram caused by Armodafinil mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[53]
Vandetanib	DMRICNP	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Vandetanib.	Solid tumour/cancer [2A00-2F9Z]	[53]
Triptorelin	DMTK4LS	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Triptorelin.	Solid tumour/cancer [2A00-2F9Z]	[53]
Pitolisant	DM8RFNJ	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Pitolisant.	Somnolence [MG42]	[53]
Telavancin	DM58VQX	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Telavancin.	Staphylococcal/streptococcal disease [1B5Y]	[53]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Escitalopram and Plicamycin.	Testicular cancer [2C80]	[54]
Fostamatinib	DM6AUHV	Moderate	Decreased metabolism of Escitalopram caused by Fostamatinib mediated inhibition of CYP450 enzyme.	Thrombocytopenia [3B64]	[78]
Caplacizumab	DMPUKA7	Moderate	Increased risk of bleeding by the combination of Escitalopram and Caplacizumab.	Thrombocytopenia [3B64]	[54]
Apixaban	DM89JLN	Moderate	Increased risk of bleeding by the combination of Escitalopram and Apixaban.	Thrombosis [DB61-GB90]	[54]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Escitalopram and Cangrelor.	Thrombosis [DB61-GB90]	[54]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Escitalopram and Brilinta.	Thrombosis [DB61-GB90]	[54]
Lenvatinib	DMB1IU4	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Lenvatinib.	Thyroid cancer [2D10]	[53]
Cabozantinib	DMIYDT4	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Cabozantinib.	Thyroid cancer [2D10]	[53]
Insulin-detemir	DMOA4VW	Moderate	Increased risk of hypoglycemia by the combination of Escitalopram and Insulin-detemir.	Type-1/2 diabete [5A10-5A11]	[50]
Insulin degludec	DMPL395	Moderate	Increased risk of hypoglycemia by the combination of Escitalopram and Insulin degludec.	Type-1/2 diabete [5A10-5A11]	[50]
Trimeprazine	DMEMV9D	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Trimeprazine.	Vasomotor/allergic rhinitis [CA08]	[68]
Betrixaban	DM2C4RF	Moderate	Increased risk of bleeding by the combination of Escitalopram and Betrixaban.	Venous thromboembolism [BD72]	[54]
Propafenone	DMPIBJK	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Propafenone.	Ventricular tachyarrhythmia [BC71]	[53]
Flecainide	DMSQDLE	Major	Increased risk of prolong QT interval by the combination of Escitalopram and Flecainide.	Ventricular tachyarrhythmia [BC71]	[53]
-----------


⏷ Show the Full List of 154 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Butylated hydroxytoluene	E00336	31404	Antioxidant
Isopropyl alcohol	E00070	3776	Antimicrobial preservative; Solvent
Mannitol	E00103	6251	Diluent; Flavoring agent; Lyophilization aid; Plasticizing agent; Tonicity agent
Propyl gallate	E00075	4947	Antimicrobial preservative; Antioxidant
Butylhydroxyanisole	E00308	24667	Antimicrobial preservative; Antioxidant
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 300	E00651	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 400	E00653	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polyethylene glycol 6000	E00655	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Polysorbate 80	E00665	Not Available	Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Povidone	E00667	Not Available	Binding agent; Coating agent; Disintegrant; Film/membrane-forming agent; Solubilizing agent; Suspending agent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 18 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Escitalopram 10 mg tablet	10 mg	Oral Tablet	Oral
Escitalopram 20 mg tablet	20 mg	Oral Tablet	Oral
Escitalopram 5 mg tablet	5 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BGP Pharma ULC: DICETEL (Pinaverium Bromide) product monograph
3	BDDCS applied to over 900 drugs
4	FDA Approved Drug Products: Lexapro (escitalopram) for oral use
5	DPD Approved Drugs: Escitalopram
6	The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet. 2007;46(4):281-90. doi: 10.2165/00003088-200746040-00002.
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Antidepressants and sleep: a review. Perspect Psychiatr Care. 2009 Jul;45(3):191-7.
9	PharmGKB summary: citalopram pharmacokinetics pathway. Pharmacogenet Genomics. 2011 Nov;21(11):769-72.
10	CYP2D6 P34S Polymorphism and Outcomes of Escitalopram Treatment in Koreans with Major Depression. Psychiatry Investig. 2013 Sep;10(3):286-93.
11	Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder. Pharmacogenet Genomics. 2015 Nov;25(11):548-54.
12	Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
13	Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
14	Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
15	Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
16	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
17	Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
18	Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
19	The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
20	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
21	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
22	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
23	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
24	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
25	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
26	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
27	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
28	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
29	High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin. Hepatogastroenterology. 2003 Nov-Dec;50(54):2274-8.
30	Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys. 1997 Oct 1;346(1):161-9.
31	Cytochrome P450 pharmacogenetics and cancer. Oncogene. 2006 Mar 13;25(11):1679-91.
32	CYP2C19*17 is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2009 May;115(2):391-6.
33	Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
34	Cytochromes of the P450 2C subfamily are the major enzymes involved in the O-demethylation of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1995 Dec;353(1):116-21.
35	Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
36	A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998 May;32(5):554-63.
37	Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology. 2001 Feb;120(2):525-33.
38	Possible involvement of multiple human cytochrome P450 isoforms in the liver metabolism of propofol. Br J Anaesth. 1998 Jun;80(6):788-95.
39	Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
40	Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
41	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
42	Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
43	Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6.
44	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
45	Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
46	Achamallah NS "Visual hallucinations after combining fluoxetine and dextromethorphan ." Am J Psychiatry 149 (1992): 1406. [PMID: 1530079]
47	Beasley CM Jr, Masica DN, Heiligenstein JH, Wheadon DE, Zerbe RL "Possible monoamine oxidase inhibitor-serotonin uptake inhibitor interaction: fluoxetine clinical data and preclinical findings." J Clin Psychopharmacol 13 (1993): 312-20. [PMID: 8227489]
48	Bhatara VS, Magnus RD, Paul KL, Preskorn SH "Serotonin syndrome induced by venlafaxine and fluoxetine: a case study in polypharmacy and potential pharmacodynamic and pharmacokinetic mechanisms." Ann Pharmacother 32 (1998): 432-6. [PMID: 9562139]
49	Boyer EW, Shannon M "The serotonin syndrome." N Engl J Med 352 (2005): 1112-20. [PMID: 15784664]
50	Abad S, Moachon L, Blanche P, Bavoux F, Sicard D, Salmon-Ceron D "Possible interaction between glicazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia." Br J Clin Pharmacol 52 (2001): 456-7. [PMID: 11678792]
51	Asplund K, Wiholm BE, Lithner F "Glibenclamide-associated hypoglycaemia: a report on 57 cases." Diabetologia 24 (1983): 412-7. [PMID: 6411511]
52	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
53	Canadian Pharmacists Association.
54	Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9. [PMID: 1482806]
55	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
56	Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
57	Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
58	Product Information. Celexa (citalopram). Forest Pharmaceuticals, St. Louis, MO.
59	Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
60	Bannister SJ, Houser VP, Hulse JD, Kisicki JC, Rasmussen JG "Evaluation of the potential for interactions of paroxetine with diazepam, cimetidine, warfarin, and digoxin." Acta Psychiatr Scand Suppl 350 (1989): 102-6. [PMID: 2530759]
61	Vizcaychipi MP, Walker S, Palazzo M "Serotonin syndrome triggered by tramadol." Br J Anaesth 99 (2007): 919. [PMID: 18006535]
62	Belcastro V, Costa C, Striano P "Levetiracetam-associated hyponatremia." Seizure 17 (2008): 389-90. [PMID: 18584781]
63	Cerner Multum, Inc. "Canadian Product Information.".
64	Product Information. Cymbalta (duloxetine). Lilly, Eli and Company, Indianapolis, IN.
65	EMEA. European Medicines Agency "EPARs. European Union Public Assessment Reports.".
66	Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
67	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
68	Agencia Espaola de Medicamentos y Productos Sanitarios Healthcare "Centro de informacion online de medicamentos de la AEMPS - CIMA.".
69	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
70	Cerner Multum, Inc. "Australian Product Information.".
71	Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
72	Product Information. Zulresso (brexanolone). Sage Therapeutics, Inc., Cambridge, MA.
73	Alvine G, Black DW, Tsuang D "Case of delirium secondary to phenelzine/L-tryptophan combination." J Clin Psychiatry 51 (1990): 311. [PMID: 2365671]
74	Product Information. Savella (milnacipran). Forest Pharmaceuticals, St. Louis, MO.
75	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
76	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
77	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
78	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.